Papaverine combined with prostaglandin E2 synergistically induces neuron-like morphological changes and decrease of malignancy in human prostatic cancer LNCaP cells

Anticancer Research

Volumn 20, Issue 2 A, 2000, Pages 761-767

  Shimizu, Takahisa ^a   Ohta, Yasuyuki ^a   Ozawa, Hideyuki ^a   Matsushima, Hisashi ^b   Takeda, Ken ^a  

^a TOKYO UNIVERSITY OF SCIENCE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Differentiation; LNCaP; Papaverine; Prostaglandin E2; Prostate cancer

Indexed keywords

DIGESTIVE TRACT SPASMOLYTIC AGENT; PAPAVERINE; PROSTAGLANDIN E2; PROTEIN BCL 2;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRUCTURE; DRUG POTENTIATION; ELECTRON MICROSCOPY; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE C MYC; PRIORITY JOURNAL; PROSTATE CARCINOMA;

ACTINS; CELL DIFFERENTIATION; CELL DIVISION; DINOPROSTONE; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HUMANS; KINETICS; MALE; NEOPLASM INVASIVENESS; NEURONS; PAPAVERINE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR CELLS, CULTURED;

EID: 0034097571     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Huggins C and Hodges C: Studies on prostatic cancer. I. The effects of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293-297, 1941.
2. Lepor H, Ross A and Walish PC: The influence of hormonal therapy on survival of men with advanced prostatic cancer. J Urol 128: 335-340, 1982.
3. Koeffler HP: Induction of differentiation of human acute myelogenous cells: Therapeutic implications. Blood 62: 707-721, 1983.
4. Ohta M, Furukawa Y, Ide C, Akiyama N, Utakoji T, Miura Y and Saito M: Establishment and characterization of four human monocytoid leukemia cell lines (JOSK-I, -S, -M and -K) with capabilities of monocyte-macrophage lineage differentiation and constitutive production of interleukin 1. Cancer Res 46: 3067-3074, 1986.
5. Oka Y and Takeda K: Retinoic acid combined with GM-CSF induces morphological changes with segmented nuclei in human myeloblastic leukemia ML-1 cells. Anticancer Res 17: 1951-1956, 1997.
6. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P and Degos L: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76: 1704-1709, 1990.
7. Dahiya R, Park HD, Cusick J, Vessella RL, Fournier G and Narayan P: Inhibition of tumorigenic potential and prostate-specific antigen expression in LNCaP human prostate cancer cell line by 13-cis-retinoic acid. Int J Cancer 59: 126-132, 1994.
8. Gleave ME, Sato N, Sadar M, Yago V, Bruchovsky N and Sullivan L: Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model. J Cell Biochem 69: 271-281, 1998.
9. Bang Y-J, Pirnia F, Fang W-G, Kang WK, Sartor O, Whitesell L, Ha MJ, Tsokos M, Sheahan MD, Nguyen P, Niklinski WT, Myers CE and Trepel JB: Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci USA 91: 5330-5334, 1994.
10. Blusztajn JK, Venturini A, Jackson DA, Lee HJ and Wainer BH: Acetylcholine synthesis and release is enhanced by dibutyryl cyclic AMP in a neuronal cell line derived from mouse septum. J Neurosci 12: 793-799, 1992.
11. Chang JH and Prasad KN: Differentiation of mouse neuroblastoma cells in vitro and in vivo induced by cyclic adenosine monophosphate (cAMP). J Pediatr Surg 5: 847-858, 1976.
12. Kvanta A and Fredholm BB: Synergistic effects between protein kinase C and cAMP on activator protein-1 activity and differentiation of PC-12 pheochromocytoma cells. J Mol Neurosci 4: 205-214, 1993.
13. Sharma S, Hansen JT and Notter MF: Effects of NGF and dibutyryl cAMP on neuronal differentiation of embryonal carcinoma cells. J Dev Neurosci 8: 33-45, 1990.
14. Frodin M, Peraldi P and Van Obberghen E: Cyclic AMP activates the mitogen-activated protein kinase cascade in PC12 cells. J Biol Chem 269: 6207-6214, 1994.
15. Vossler MR, Yao H, York RD, Pan M-G, Rim CS and Stork PJS: cAMP activates MAP kinase and Elk-1 through a B-Raf-and Rapl-dependent pathway. Cell 89: 73-82, 1997.
16. Kipl a cyclin-dependent kinase inhihitor, and neuron-like morphology in LNCaP prostate tumor cells. Biochem Bioph Res Comm 257: 609-614, 1999.
17. Hsieh TC, Xu W and Chiao JW: Growth regulation and cellular changes during differentiation of human prostatic cancer LNCaP cells as induced by T lymphocyte-conditioned medium. Exp Cell Res 218: 137-143, 1995.
18. Tai G, Eun-Young J, Yuji H, Masahiko K, Toshio H, Kenji K, Kenshi F and Mitsufumi M: Different effects of cyclic AMP and butyrate on eosinophilic differentiation, apoptosis and bcl-2 expression of a human eosinophilic leukemia cell line, EoL-1. Hematol Oncol 14: 181-192, 1996.
19. Ren W, Kinniburgh AJ and Dziak R: Regulation of C-myc protooncogene expression in osteoblastic cells by arachidonic acid metabolites: relationship to proliferation. Calcif Tissue Int 50: 372-377, 1992.
20. 3 vitamin D3-induced c-myc reduction during HL-60 cell differentiation. Leukemia Res 12: 597-605, 1988.